Clinuvel Pharmaceuticals Ltd (CLVLF) SEC Filings

Clinuvel Pharmaceuticals Ltd (CUVL) reports that it will release its financial results for the year ending 30 June 2026 on 27 August 2026. Management will host an investor and analyst webinar the same day from 18:00 to 18:30 AEST to review the results.

The webinar will be accessible online via Zoom, with participants able to submit questions during registration and throughout the event. The company also reiterates its focus on melanocortin-based therapies, including its lead approved treatment SCENESSE for erythropoietic protoporphyria across several major regions.

Clinuvel Pharmaceuticals reports progress on its VLRX-L controlled-release injectable liquid peptide platform. After pre-clinical evaluation of four candidate formulations, one formulation showed a superior release profile over the targeted delivery window, with lower peak plasma levels and sustained drug levels over the dosing period. The company’s Singapore-based RD&I Centre, VALLAURIX, is now refining this lead candidate. Pending final optimisation and results, further pre-clinical studies are planned for Q1 2027, and manufacturing scale-up is being scoped. The initial focus for VLRX-L is melanocortin peptides, aimed at enabling flexible, individualised dosing for different patient populations.

Clinuvel Pharmaceuticals provided a commercial update on vitiligo, outlining benchmarks for current therapies and the development of its lead melanocortin drug SCENESSE® (afamelanotide) with adjunct narrowband UVB (NB-UVB) as a systemic repigmentation approach for patients with extensive disease affecting at least 10% of body surface area.

The update reviews published response rates for NB-UVB and topical and oral Janus kinase (JAK) inhibitors, then notes early CUV105 data showing visible, lasting repigmentation in 12 SCENESSE® plus NB-UVB case reports and prior trials where the combination outperformed NB-UVB alone, while afamelanotide monotherapy was ineffective. Clinuvel states it has reinforced supply chains, expanded North American infrastructure, engaged more than 100 prospective Specialty Centers, anticipates CUV105 topline results in December 2026, and indicates the anticipated start of pivotal CUV107 in November 2026.

CLINUVEL PHARMACEUTICALS provided an update on the clinical and regulatory path for SCENESSE® (afamelanotide) in vitiligo. Late-stage study CUV105 has enrolled 210 darker-skinned patients (Fitzpatrick III–VI), comparing SCENESSE® plus narrowband UVB (NB-UVB) to NB-UVB alone over a 20-week treatment period, with topline results anticipated in December 2026. Key endpoints are T-VASI50 (≥50% total body repigmentation) and F-VASI75 (≥75% facial repigmentation), supported by central photographic analysis.

CUV105 will be followed by pivotal Phase III study CUV107. The European Medicines Agency reviewed the CUV107 protocol in April 2026, and it was agreed to include 300 vitiligo patients with darker skin types (Fitzpatrick IV–VI). CUV107 is anticipated to start in November 2026 with a planned 12-month recruitment, assessing repigmentation, durability of response and safety. SCENESSE® is already approved for erythropoietic protoporphyria in several regions but is not yet approved for vitiligo.

Clinuvel Pharmaceuticals Limited, a foreign private issuer, submitted a Form 6-K for July 2026 stating that it had lodged with the Australian Securities Exchange an announcement titled “Appendix 3H - Notification of cessation of securities,” which is included as Exhibit 99.1 for U.S. investors.

Clinuvel Pharmaceuticals Limited announced a strategic reorganisation under which its corporate headquarters and key functions will relocate to the United States, with changes effective 1 January 2027. Operations and resources will be refocused exclusively on the U.S. pharmaceutical pipeline, commercial strategy, and capital markets.

The plan includes a global workforce reduction of approximately 10%-20% and relocation of selected functions to the U.S. to better align operating expenditure with current revenue generation and near-term clinical and commercial priorities. Management highlights the U.S. as representing over 40% of the global pharmaceutical market by value and a primary ecosystem for premium pricing, regulatory advancement, and M&A activity.

The reorganisation reflects that over 66% of Clinuvel’s shareholder register is held by foreign investors and that late-stage programs, particularly in vitiligo, mainly target an estimated six million affected U.S. patients. Leadership states that a U.S. focus is viewed as the most effective way to realise the intrinsic value of the company’s assets and expand access to global healthcare investors.

Clinuvel Pharmaceuticals Limited reports that its American Depositary Share (ADS) began trading on the Nasdaq Stock Market on 20 July 2026 (New York time) under the ticker CUVL. This trading start completes the uplift of its previous Level I American Depositary Receipt CLVLY to a Level II ADS program.

The company is a global biopharmaceutical group focused on melanocortin peptide therapies for genetic, metabolic, and dermatological disorders. Its lead therapy SCENESSE® (afamelanotide 16mg) is approved for commercial distribution in Europe, the USA, Canada, Israel, and Australia for adult patients with erythropoietic protoporphyria (EPP).

CLINUVEL PHARMACEUTICALS LIMITED reports that its American Depositary Share (ADS) is expected to commence trading on the Nasdaq Stock Market on 20 July 2026 under the ticker CUVL, after the U.S. SEC deemed its publicly filed Form 20-F Registration Statement effective on 17 July and Nasdaq approved the listing.

The company’s existing over-the-counter ADR CLVLY will be upgraded from Level I to a Level II ADS on Nasdaq, with each ADS representing one ordinary share listed on the ASX. CLINUVEL does not propose to raise capital or issue new shares as part of this upgraded depositary share program, and current CLVLY holders are not required to take any action. CUVL will trade on the Nasdaq Global Select Market, which provides greater visibility among U.S. investors. CLINUVEL highlights this move as part of a broader shift of its business toward North America while continuing to commercialise its lead therapy SCENESSE.

Clinuvel Pharmaceuticals Limited and The Bank of New York Mellon outline the terms governing Clinuvel’s American Depositary Shares, each representing one ordinary share of the Australian company. The revised receipt form reflects that Clinuvel is now subject to periodic reporting under the U.S. Securities Exchange Act of 1934, giving ADS holders access to the company’s SEC-filed reports via EDGAR. The document describes how ADSs are issued, transferred, and surrendered in exchange for underlying shares, including the ability to hold ADSs in certificated or uncertificated (book-entry/DRS) form.

The text details fees and charges borne by ADS holders, such as up to $5.00 per 100 ADSs for issuance or surrender, and up to $0.05 per ADS for cash and annual depositary services. It explains dividend conversion from foreign currency into U.S. dollars, tax withholding, voting procedures for underlying shares, treatment of corporate actions (rights issues, tender offers, redemptions, replacements), and circumstances under which the depositary may suspend deposits, withdrawals, or terminate the program. Liability limitations, amendment and termination mechanics, DTC’s Direct Registration and Profile systems, New York jurisdiction, and jury trial and sovereign immunity waivers are also set out for ADS owners.